[Diabetes mellitus and pancreatic cancer - cause or result?].
Incretin glucagon like peptid-1 receptor agonists are also known as incretin mimetics. These are the new drugs for the treatment of type 2 diabetes, which have a significant antihyperglycemic effect. For the individual treatment can be used short- acting and long-acting drugs. In addition to glucose effect there are influenced another factors, especially weight and hypertension. The patophysiological mechanism of their action, pharmacological and clinical differences and their use in clinical practice are described.Key words: glucagon-like peptid 1 - glucagon-like peptid 1 agonists short-acting/long-acting - clinical effects.